Voluntis said today its digital management system for people with Type II diabetes, Insulia, won FDA clearance and CE Mark approval to integrate Sanofi‘s (NYSE:SNY) Toujeo insulin glargine. The company’s software already works with Lantus and Levemir.
The Insulia digital companion is composed of a patient mobile app and healthcare worker web portal. The app gives real-time basal insulin dosing recommendations and educational coaching messages based on blood glucose levels to patients with Type II diabetes. The web portal enables healthcare practitioners to develop personalized treatment plans and track their patient population remotely.
Get the full story at our sister site, Drug Delivery Business News.
The post Voluntis wins regulatory nod to integrate Toujeo insulin with Insulia mobile app appeared first on MassDevice.